Macular Degeneration we know is a serious issue. It accounts for the greatest number of people going blind in an age group greater than 50 years of age. With an aging population this potentially will become an enormous burden on society in the near future.
Finally though we seem to have some great news from a study done in Denmark. In the last 5 years or so a treatment finally has been developed, which seems to have halved the rate of new cases of blindness appearing. The study compared new cases of blindness documented in the year 2000 versus new cases in 2010.
This treatment does not sound great because it involves injecting a drug called Lucentis into the eye, as often as every month!
Even though this treatment might sound very pleasant, the alternative of going blind you have to admit is even less pleasant. What is clear from the many patients we have referred for this treatment is that once you have experienced the process it is not so bad. In fact some patients will go as far as saying that giving blood is more unpleasant.
The drug Lucentis is from a family of drugs called anti vascular endothelial growth factors (anti-VEGFs). The company that makes Lucentis specifically for macular degeneration makes another drug from this family called Avastin. Avastin is used for treatment of colon cancer.

So why I are we talking about a colon cancer drug in a macular degeneration article? Very simple reason is that because both these drugs are similar in chemical formula retinal specialists a while back started to use Avastin off label for macular degeneration. Off label means that the drug has not gone through extensive trials for macula degeneration. It had only been extensively tested for colon cancer.
The results though seem to be equivalent to Lucentis and very importantly, Avastin is around 1/10th of the cost. This is such a big issue that the American government body NEI has now sponsored a trial using the two drugs head to head. Preliminary data seems to show that they are equivalent and maybe interchangeable. In an era where health care is becoming horrendously expensive, this type of trial is very important.
Anti-VEGFs are now the standard of care for macular degeneration around the world and it will be interesting to see whether the Denmark experience is repeated in other countries. We suspect it will!
The article mentions that Israel seems to be experiencing a significant lowering of blindness, which seems to be related to the use of anti-VEGFs. For those interested the article can be found by CLICKING HERE.
Even though these studies are exciting news for macular degeneration, this is not a cure. The key is still to have regular comprehensive eye examinations. Always ask your eye practitioner if they have checked your macula. The later macular degeneration is discovered the less effective any treatment will be.
At The Eye Practice detection of eye disease and preserving your vision is our priority. Call us on 92901 1899 or BOOK ONLINE HERE.


